Hyphens Pharma International Limited (SGX:1J5)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.3200
+0.0100 (3.23%)
At close: Mar 20, 2026
Market Cap98.84M +16.4%
Revenue (ttm)177.37M -9.2%
Net Income5.84M -42.7%
EPS0.02 -42.6%
Shares Out308.87M
PE Ratio17.20
Forward PE8.00
Dividend0.02 (4.69%)
Ex-Dividend DateMay 7, 2025
Volume10,400
Average Volume91,245
Open0.3200
Previous Close0.3100
Day's Range0.3150 - 0.3200
52-Week Range0.2600 - 0.3950
Beta0.09
RSI44.72
Earnings DateFeb 26, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Pia... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 474
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 1J5
Full Company Profile

Financial Performance

In 2025, SGXC:1J5's revenue was 177.37 million, a decrease of -9.24% compared to the previous year's 195.42 million. Earnings were 5.84 million, a decrease of -42.67%.

Financial Statements